Full-Time

Outreach Phlebotomist

Mass General Brigham

Mass General Brigham

1-10 employees

Early-stage life science venture investor

Compensation Overview

$20.90 - $25.28/hr

+ $3,000 sign-on bonus

Salem, MA, USA

In Person

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Phlebotomy
Patient Care
Customer Service
HIPAA

Get referred to Mass General Brigham

See people who can refer or advise you

Requirements
  • A high school diploma or equivalent is required.
  • Completion of a phlebotomy course is preferred.
  • A Class D passenger vehicle driver's license is preferred.
  • Demonstrated proficiency in proper collection methods and processing of specimens, including correct tube selection, volume, and stability requirements.
  • Ability to prioritize work, manage time, and adjust to changes in work volumes and projects.
  • Superior customer service skills, including empathy and respect for patients' privacy and autonomy.
  • Ability to work independently and collaborate effectively within a team.
  • Ability to work fluently with computer programs and systems and comply with HIPAA regulations.
Responsibilities
  • Obtain quality blood samples using a variety of phlebotomy methods for patients of all age groups.
  • Ensure accurate patient identification, specimen labeling, processing, handling, and transportation.
  • Assist in the recovery of patients experiencing adverse reactions and provide a rapid response to medical emergencies in the inpatient setting.
  • Communicate with patients and patient care teams, explain procedures, and address patient concerns.
  • Handle sharps and biohazardous materials in accordance with regulatory requirements.
  • Perform test administration and specimen collection as assigned.
Desired Qualifications
  • Completion of a phlebotomy course.
  • Class D passenger vehicle driver's license.

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2025 operating income reached $59 million after a $53 million reorganization charge.
  • Mead Johnson expanded a five-year research partnership with MGB in April 2026.
  • MGB bridge funding keeps NIH-dependent researchers alive through August 2026 deadlines.

What critics are saying

  • Brigham nurses struck July 2026 after a five-day lockout over wages and insurance.
  • MGB closed the Weiner Center, Burn Unit, and iCMP, angering clinicians.
  • Repeated labor conflict and service cuts threaten talent retention and patient trust.

What makes Mass General Brigham unique

  • Mass General Brigham runs nearly $2 billion in research and 3,700 trials.
  • Its 2026 MIT seed program linked 17 translational teams across engineering and care.
  • MGB controls first-look access to discoveries from Harvard-affiliated hospitals and investigators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

401(k) Company Match

Parental Leave

Adoption Assistance

Childcare Support

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Company News

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.

Associated Press
May 13th, 2026
Violet Therapeutics raises $4.75M to advance synaptic preservation therapy for neurodegenerative diseases

Violet Therapeutics, a biotechnology company developing therapies for neurodegenerative diseases, has raised $4.75 million in a seed extension round led by Lifespan Vision Ventures. Dementia Discovery Fund, UTEC, Ono Venture Investment and Mass General Brigham Ventures also participated. The Cambridge-based company will use the funding to advance its lead small molecule programme targeting EphB3 through IND-enabling activities. The therapy aims to halt and potentially reverse cognitive decline through glial-mediated synaptic preservation, addressing synaptic loss, the strongest predictor of cognitive decline in Alzheimer's and other neurodegenerative diseases. Violet's proprietary CONNECT platform maps cell-cell interaction networks to identify novel therapeutic targets. Founded by Mass General Brigham Ventures with researchers from Brigham and Women's Hospital, the company is developing first-in-class CNS therapies.

PR Newswire
Apr 23rd, 2026
Brigham nurses to picket as MGB executives earn $35.9M amid service closures and 0% wage offer

Registered nurses at Brigham and Women's Hospital will hold an informational picket on 29 April, protesting Mass General Brigham's corporate decisions affecting patient care and workforce conditions. The Massachusetts Nurses Association represents the nurses, who will demonstrate from 14:00 to 16:00 outside the hospital at 75 Francis Street, Boston. Nurses cite several service closures under MGB, including the Weiner Centre, Burn Unit and Integrated Care Management Programme. They criticise the health system's bargaining proposals, particularly a 0% wage offer for nurses below top step, whilst MGB reported a $59.2 million operating gain in 2025 and paid its top 14 executives $35.9 million in fiscal year 2024. The informational picket will not disrupt patient care, with nurses participating outside working hours.

PR Newswire
Mar 19th, 2026
MGB Home Care clinicians to picket Mass General over stalled contract talks after year of bargaining

Approximately 450 clinicians at Mass General Brigham Home Care, represented by the Massachusetts Nurses Association, will hold an informational picket on 24 March outside Massachusetts General Hospital. The clinicians are seeking their first union contract after more than 20 bargaining sessions since March 2025. The bargaining unit includes registered nurses, occupational therapists, physical therapists, speech language pathologists, social workers and dieticians who voted to join the MNA in June 2024. They are demanding reasonable caseload limits, clear productivity standards, competitive wages and recruitment protections. MGB reported a $59.2 million operating gain in the year ending September 2025, with CEO Dr Anne Klibanski's compensation rising 40% to $8.4 million in 2024. The picket is scheduled for 15:30 to 17:00 and is not a strike.